Clinical Trial Update: Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating progression-free survival in patients with unresectable, locally advanced pancreatic cancer treated with microwave ablation in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Baki Topal | Conditions: Pancreatic Cancer Non-resectable | Phase 2 | Status: COMPLETED